Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.77M P/E - EPS this Y 88.30% Ern Qtrly Grth -
Income -17.61M Forward P/E -0.18 EPS next Y 36.40% 50D Avg Chg -4.00%
Sales 80k PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.77 EPS next 5Y - 52W High Chg -74.00%
Recommedations 1.50 Quick Ratio 0.97 Shares Outstanding 1.97M 52W Low Chg 24.00%
Insider Own 4.82% ROA -102.53% Shares Float 1.76M Beta 0.52
Inst Own 18.03% ROE -570.69% Shares Shorted/Prior 47.64K/54.32K Price 0.62
Gross Margin 100.00% Profit Margin - Avg. Volume 71,251 Target Price 11.00
Oper. Margin -91,100.00% Earnings Date Nov 11 Volume 24,738 Change 0.98%
About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Cyclacel Pharmaceuticals, Inc. News
12/05/24 Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
11/15/24 Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
11/14/24 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
11/13/24 Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
11/12/24 Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
11/12/24 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
10/24/24 Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
10/23/24 Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
10/09/24 Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
09/25/24 Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
09/04/24 Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
09/03/24 Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
09/02/24 Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
08/18/24 Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
08/14/24 Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
08/14/24 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
08/07/24 Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
07/25/24 Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
08:15 AM Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
06/06/24 All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy